Increased levels of CRP and MCP-1 are associated with previously unknown abnormal glucose regulation in patients with acute STEMI: a cohort study

Cardiovascular Diabetology

Original Investigation

Eva C Knudsen¹  Geir Ø Andersen¹  Harald Arnesen²  Ingebjørg Seljeflot²  Abdelnoor Michael³  Arild Mangschau⁴  Jan Eritsland⁴  Carl Müller⁵ 

[1] Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Oslo, Norway;Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway;Center for Heart Failure Research, Oslo University Hospital, Ullevål, Oslo, Norway;Center for Clinical Heart Research, Oslo University Hospital, Ullevål, Oslo, Norway;Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway;Center for Heart Failure Research, Oslo University Hospital, Ullevål, Oslo, Norway;Faculty of Medicine, University of Oslo, Oslo, Norway;Center of Clinical Research, Unit of Epidemiology and Biostatistics, Oslo University Hospital, Ullevål, Oslo, Norway;Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway;Center for Heart Failure Research, Oslo University Hospital, Ullevål, Oslo, Norway;Nuclear Medicine, Oslo University Hospital, Ullevål, Oslo, Norway;

关键词: Percutanous Coronary Intervention;    Inflammatory Marker;    Oral Glucose Tolerance Test;    Impaired Glucose Tolerance;    Impaired Fasting Glucose;   

DOI  :  10.1186/1475-2840-9-47

 received in 2010-07-02, accepted in 2010-09-02,  发布年份 2010

来源: Springer

【 摘 要 】

BackgroundInflammation plays an important role in the pathophysiology of both atherosclerosis and type 2 diabetes and some inflammatory markers may also predict the risk of developing type 2 diabetes. The aims of the present study were to assess a potential association between circulating levels of inflammatory markers and hyperglycaemia measured during an acute ST-elevation myocardial infarction (STEMI) in patients without known diabetes, and to determine whether circulating levels of inflammatory markers measured early after an acute STEMI, were associated with the presence of abnormal glucose regulation classified by an oral glucose tolerance test (OGTT) at three-month follow-up in the same cohort.MethodsInflammatory markers were measured in fasting blood samples from 201 stable patients at a median time of 16.5 hours after a primary percutanous coronary intervention (PCI). Three months later the patients performed a standardised OGTT. The term abnormal glucose regulation was defined as the sum of the three pathological glucose categories classified according to the WHO criteria (patients with abnormal glucose regulation, n = 50).ResultsNo association was found between inflammatory markers and hyperglycaemia measured during the acute STEMI. However, the levels of C-reactive protein (CRP) and monocyte chemoattractant protein-1 (MCP-1) measured in-hospital were higher in patients classified three months later as having abnormal compared to normal glucose regulation (p = 0.031 and p = 0.016, respectively). High levels of CRP (≥ 75 percentiles (33.13 mg/L)) and MCP-1 (≥ 25 percentiles (190 ug/mL)) were associated with abnormal glucose regulation with an adjusted OR of 3.2 (95% CI 1.5, 6.8) and 7.6 (95% CI 1.7, 34.2), respectively.ConclusionElevated levels of CRP and MCP-1 measured in patients early after an acute STEMI were associated with abnormal glucose regulation classified by an OGTT at three-month follow-up. No significant associations were observed between inflammatory markers and hyperglycaemia measured during the acute STEMI.

【 授权许可】

CC BY   
© Knudsen et al; licensee BioMed Central Ltd. 2010